Genentech
Genentech has 2 source-linked AI deployments documented in AIUseCaseHub, across 2 industries and 2 countries.
Hyperscaler mix
See whether Genentech's cases are powered by Microsoft, AWS, GCP, or multiple providers.
How Genentech builds AI
Build / Buy / Compose across this company's documented cases
2 of 2 cases classified (100%) · Compare all use-case types
Reported outcomes
1 case reports measurable results
−75%
Time & speed
median · 2 metrics
Medians of results published in Genentech cases, normalized for comparability. See all benchmarks →
Evidence persistence
1 of 1 judgeable case is still publicly referenced · 1 show the organization expanding AI use.
Durability of public evidence, not whether systems remain in production. How this is measured →
Technology snapshot
What Genentech uses across visible cases
Capability flags and technologies mentioned in the indexed use cases on this page.
- Top use case
- Fine-tuning
- Tagged cases
- 1/2
- Tech names
- 7
All Use Cases (2)
Genentech leverages generative AI with Amazon Bedrock Agents to accelerate drug discovery
Genentech uses Amazon Bedrock Agents with Anthropic Claude Sonnet 3.5 to automate complex biomedical research workflows for biomarker validation.The gRED Research Agent processes and synthesizes information from millions of scientific data sources using multi-agent collaboration and Retrieval Augmented Generation (RAG).This automation reduces manual research time from weeks to minutes, freeing scientists to focus on high-impact tasks and accelerating drug discovery.
Microsoft
AstraZeneca and Novartis Scale AI Across Pharma Value Chain
This article provides a comprehensive overview of how leading pharmaceutical firms—including AstraZeneca, Novartis, Sanofi, GSK, Genentech, and AbbVie—are integrating Microsoft technologies such as Azure AI, Machine Learning, Cognitive Services, and Power Platform to transform drug development and operations. Real-world examples cover AI-powered drug target identification, generative molecule design, clinical trial acceleration, pharmacovigilance, supply chain optimization, and patient engagement via chatbots. The piece details both the tangible business benefits (shortened timelines, reduced costs, improved trial precision, and better patient outcomes) and persistent challenges such as data fragmentation, legacy systems, regulatory complexities, and change management. Strategic priorities for CIOs and IT leaders on how to industrialize AI, ensure enterprise-wide adoption, and promote responsible, cross-functional scaling of Microsoft technologies are emphasized. The article highlights collaborations like AstraZeneca’s enterprise AI roadmap, Novartis-Microsoft innovation lab, and Sanofi’s infrastructure modernization to demonstrate mature, scalable uses of cloud-based AI.Challenges with data interoperability, legacy infrastructure, talent and cultural adoption, and regulatory risk are addressed alongside solutions such as human-in-the-loop designs, explainable AI, and real-time learning cycles aligned with scientific and compliance goals.